Skip to main content
NCBI home page
Gut logoLink to Gut
. 1997 Aug;41(2):181–186. doi: 10.1136/gut.41.2.181

Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer

K Bardhan 1, C Dallaire 1, H Eisold 1, A Duggan 1
PMCID: PMC1891448  PMID: 9301496

Abstract

Background/Aims—To investigate the effect of the new Helicobacter pylori eradication regimen, ranitidine bismuth citrate (RBC) and clarithromycin (CLAR) dual therapy, on duodenal ulcer healing and absence of ulcer recurrence during 24 weeks follow up (overall success). 
Methods—Two hundred and thirty two H pylori positive patients with active duodenal ulcer received four weeks treatment with RBC 400 mg twice daily alone (RBC400) (n=82), or RBC 400 or 800mg twice daily co-prescribed with clarithromycin 250 mg four times daily for 14 days, followed by 14 days of RBC 400 mg twice daily alone (RBC400+CLAR and RBC 800+CLAR, respectively, n=75 for each). 
Results—The co-prescription regimens gave high H pylori eradication rates determined using two tests (CLOtest and 13C-urea breath test) for the presence of the organism. These rates were 92% and 81% for RBC400+CLAR (n=62) and RBC800+CLAR (n=63) respectively, compared with 2% for RBC400 (n=66) (p<0.001). With respect to overall success as estimated by life table analysis, RBC400+CLAR (89%) and RBC800+ CLAR (87%) were significantly more effective than RBC400 alone (51%) (p<0.001). All regimens were safe and well tolerated. Trough plasma bismuth concentrations at week 4 were low (treatment medians less than 6.6 ng bismuth/ml). 
Conclusions—Ranitidine bismuth citrate is a well tolerated and efficacious ulcer healing drug which, when co-prescribed with clarithromycin, affords effective H pylori eradication therapy and prevents ulcer relapse in most patients with duodenal ulcer. 



Keywords: ranitidine bismuth citrate; duodenal ulcer; Helicobacter pylori eradication

Full Text

The Full Text of this article is available as a PDF (138.9 KB).

Figure 1 .

Figure 1

Open in a new tab

: Cumulative overall success rates—life table analysis. Numbers at the bottom of the graph are of patients assessed at each time point in the three different treatment groups. Overall success, the primary end point, combines in a single value the proportions of patients whose ulcer healed and remained so at the end of 24 weeks' follow up. 


Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axon A. T., Ireland A., Smith M. J., Rooprams P. D. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1997 Feb;11(1):81–87. doi: 10.1046/j.1365-2036.1997.116287000.x. [DOI] [PubMed] [Google Scholar]
  2. Bardhan K. D., Dekkers C. P., Lam S. K., Nowak A., Schaffalitzky de Muckadell O. B., Schutze K., Tildesley G., Kler L., Forster J. K., Lacey L. F. GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Ther. 1995 Oct;9(5):497–506. doi: 10.1111/j.1365-2036.1995.tb00412.x. [DOI] [PubMed] [Google Scholar]
  3. Chiba N., Rao B. V., Rademaker J. W., Hunt R. H. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992 Dec;87(12):1716–1727. [PubMed] [Google Scholar]
  4. Dixon J. S. Helicobacter pylori eradication: unravelling the facts. Scand J Gastroenterol Suppl. 1995;212:48–62. [PubMed] [Google Scholar]
  5. Dobrilla G., Vallaperta P., Amplatz S. Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials. Gut. 1988 Feb;29(2):181–187. doi: 10.1136/gut.29.2.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hentschel E., Brandstätter G., Dragosics B., Hirschl A. M., Nemec H., Schütze K., Taufer M., Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993 Feb 4;328(5):308–312. doi: 10.1056/NEJM199302043280503. [DOI] [PubMed] [Google Scholar]
  7. McLean A. J., McCarthy P., Dudley F. J. Cytoprotective agents and ulcer relapse. Med J Aust. 1985 Feb 4;142(Spec No):S25–S28. doi: 10.5694/j.1326-5377.1985.tb128347.x. [DOI] [PubMed] [Google Scholar]
  8. Miller J. P., Faragher E. B. Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J (Clin Res Ed) 1986 Nov 1;293(6555):1117–1118. doi: 10.1136/bmj.293.6555.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Peterson W. L., Ciociola A. A., Sykes D. L., McSorley D. J., Webb D. D. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Aliment Pharmacol Ther. 1996 Jun;10(3):251–261. doi: 10.1111/j.0953-0673.1996.00251.x. [DOI] [PubMed] [Google Scholar]
  11. Peterson W. L., Graham D. Y., Marshall B., Blaser M. J., Genta R. M., Klein P. D., Stratton C. W., Drnec J., Prokocimer P., Siepman N. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol. 1993 Nov;88(11):1860–1864. [PubMed] [Google Scholar]
  12. Stables R., Campbell C. J., Clayton N. M., Clitherow J. W., Grinham C. J., McColm A. A., McLaren A., Trevethick M. A. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther. 1993 Jun;7(3):237–246. doi: 10.1111/j.1365-2036.1993.tb00094.x. [DOI] [PubMed] [Google Scholar]
  13. Wyeth J. W., Pounder R. E., Duggan A. E., O'Morain C. A., Schaufelberger H. D., De Koster E. H., Rauws E. A., Bardhan K. D., Gilvarry J., Buckley M. J. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996 Aug;10(4):623–630. doi: 10.1046/j.1365-2036.1996.46188000.x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES